CMS has released their latest round of drug pricing data – another peek into the functionality of the prescription drug supply chain amid the COVID-19 pandemic. As we highlighted in the June and July NADAC reports, generic drug prices are weathering the pandemic storm. In fact, not only have the predictions of massive increases failed to come to fruition, but instead, generic drug prices are falling. This month continues that trend. Our latest report digs into the numbers using the latest NADAC drug pricing data from CMS.
Read More
In our recent deep dive into the warped incentives in Medicare Part D that give rise to zombie brand drugs and excess costs for seniors and taxpayers, we noticed how helpful Medicare Plan Finder is in assisting seniors choose a health plan. However, we also found that it was less than helpful in assisting seniors minimize their out-of-pocket drug costs. Today’s Flash Finding highlights how Plan Finder makes it exceedingly difficult for anyone to know if they can save significant money on their prescription drugs.
Read More
CMS has released their latest round of drug pricing data, giving us further insights into how the prescription drug supply chain is responding to the new challenges and demands presented by the COVID-19 pandemic. While many expected the pressures to cause massive shortages and price increases, the data shows that while shortages have definitely jumped, this new CMS drug pricing data shows that not only have generic drug prices stayed in check, but they actually appear to be deflating! But of course, the details matter, and we’ve got them for you.
Read More